Identification of Genetic Factors Implicated in Orofacial Cleft Using Whole Exome Sequencing
- Conditions
- Cleft Lip and Palate
- Registration Number
- NCT03065686
- Lead Sponsor
- Centre Hospitalier Universitaire, Amiens
- Brief Summary
Despite significant progress made in identification on numerous genes and gene pathways critical for craniofacial development, several approaches, ie mutation screening of specific candidates, association studies and even genome-wide scans have largely failed to reveal the molecular basis of NS human clefting
- Detailed Description
Despite significant progress made in identification on numerous genes and gene pathways critical for craniofacial development, several approaches, ie mutation screening of specific candidates, association studies and even genome-wide scans have largely failed to reveal the molecular basis of NS human clefting. Moreover, the efficiency of Whole Exome Sequencing -WES- was proven. The efficiency of WES was proven by the identification of the genes causing Freeman Sheldon and Miller's syndrome, followed by several others. In the Picardy region, management and follow-up of orofacial cleft patients are well-organised by a multidisciplinary team in the university hospital of Amiens. The investigators therefore decided to perform whole exome sequencing (WES) on precisely phenotyped non-syndromic CL/P patients followed in our center.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
- Subject with a NSCL/P or CL/P of unknown etiology,
- national health care insurance holders
- Subject with a CL/P of known etiology,
- Subject with a NSCL/P and an IRF6 mutation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Identification of genetic factors Day 1 Identification of genetic factors implicated in orofacial cleft using whole exome sequencing (WES).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
CHU Amiens Picardie
🇫🇷Amiens, France
CHU Amiens Picardie🇫🇷Amiens, FranceBénédicte DEMEER, MDContact+33 3 22 08 75 81demeer.benedicte@chu-amiens.fr